{"dosingGuidelines":[{"objCls":"Guideline","id":"PA166104945","name":"Annotation of CPIC Guideline for mercaptopurine and TPMT"},{"objCls":"Guideline","id":"PA166104965","name":"Annotation of CPIC Guideline for thioguanine and TPMT"},{"objCls":"Guideline","id":"PA166104933","name":"Annotation of CPIC Guideline for azathioprine and TPMT"}],"literatureAnnotation":{"id":827859423,"history":[],"literature":{"id":6690400,"resourceId":"21270794","title":"Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.","authors":["Relling M V","Gardner E E","Sandborn W J","Schmiegelow K","Pui C-H","Yee S W","Stein C M","Carrillo M","Evans W E","Klein T E","Clinical Pharmacogenetics Implementation Consortium"],"journal":"Clinical pharmacology and therapeutics","month":3,"page":"387-91","pubDate":"2011-03-01T00:00:00-08:00","sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/21270794","summary":"Thiopurine methyltransferase (TPMT) activity exhibits monogenic co-dominant inheritance, with ethnic differences in the frequency of occurrence of variant alleles. With conventional thiopurine doses, homozygous TPMT-deficient patients (~1 in 178 to 1 in 3,736 individuals with two nonfunctional TPMT alleles) experience severe myelosuppression, 30-60% of individuals who are heterozygotes (~3-14% of the population) show moderate toxicity, and homozygous wild-type individuals (~86-97% of the population) show lower active thioguanine nucleolides and less myelosuppression. We provide dosing recommendations (updates at http://www.pharmgkb.org) for azathioprine, mercaptopurine (MP), and thioguanine based on TPMT genotype.","type":"article","volume":"89","xrefs":[{"id":769164748,"resource":"PubMed","sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/21270794","xrefId":"21270794"},{"id":1449245875,"resource":"Digital Object Identifiers","sameAs":"http://dx.doi.org/10.1038%2Fclpt.2010.320","xrefId":"10.1038/clpt.2010.320"},{"id":1449245874,"resource":"PubMed Central","sameAs":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098761","xrefId":"PMC3098761"}],"year":2011},"relatedObjects":[{"objCls":"Gene","id":"PA356","symbol":"TPMT","name":"thiopurine S-methyltransferase"},{"objCls":"Disease","id":"PA443937","name":"Drug Toxicity"},{"objCls":"Disease","id":"PA444761","name":"Leukemia, Myeloid"},{"objCls":"Disease","id":"PA165817398","name":"Myelosuppression"},{"objCls":"Chemical","id":"PA448515","name":"azathioprine"},{"objCls":"Chemical","id":"PA450379","name":"mercaptopurine"},{"objCls":"Chemical","id":"PA451663","name":"thioguanine"}]},"publication":{"id":6690400,"resourceId":"21270794","title":"Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.","authors":["Relling M V","Gardner E E","Sandborn W J","Schmiegelow K","Pui C-H","Yee S W","Stein C M","Carrillo M","Evans W E","Klein T E","Clinical Pharmacogenetics Implementation Consortium"],"journal":"Clinical pharmacology and therapeutics","month":3,"page":"387-91","pubDate":"2011-03-01T00:00:00-08:00","sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/21270794","summary":"Thiopurine methyltransferase (TPMT) activity exhibits monogenic co-dominant inheritance, with ethnic differences in the frequency of occurrence of variant alleles. With conventional thiopurine doses, homozygous TPMT-deficient patients (~1 in 178 to 1 in 3,736 individuals with two nonfunctional TPMT alleles) experience severe myelosuppression, 30-60% of individuals who are heterozygotes (~3-14% of the population) show moderate toxicity, and homozygous wild-type individuals (~86-97% of the population) show lower active thioguanine nucleolides and less myelosuppression. We provide dosing recommendations (updates at http://www.pharmgkb.org) for azathioprine, mercaptopurine (MP), and thioguanine based on TPMT genotype.","type":"article","volume":"89","xrefs":[{"id":769164748,"resource":"PubMed","sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/21270794","xrefId":"21270794"},{"id":1449245875,"resource":"Digital Object Identifiers","sameAs":"http://dx.doi.org/10.1038%2Fclpt.2010.320","xrefId":"10.1038/clpt.2010.320"},{"id":1449245874,"resource":"PubMed Central","sameAs":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098761","xrefId":"PMC3098761"}],"year":2011},"related":{"GENE":[{"objCls":"Gene","id":"PA356","symbol":"TPMT","name":"thiopurine S-methyltransferase"}],"DISEASE":[{"objCls":"Disease","id":"PA443937","name":"Drug Toxicity"},{"objCls":"Disease","id":"PA444761","name":"Leukemia, Myeloid"},{"objCls":"Disease","id":"PA165817398","name":"Myelosuppression"}],"CHEMICAL":[{"objCls":"Chemical","id":"PA448515","name":"azathioprine"},{"objCls":"Chemical","id":"PA450379","name":"mercaptopurine"},{"objCls":"Chemical","id":"PA451663","name":"thioguanine"}]},"relationships":[{"id":1184519001,"history":[],"literature":[{"id":6690400,"resourceId":"21270794","title":"Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.","sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/21270794","type":"article"}],"object1s":[{"objCls":"Gene","id":"PA356","symbol":"TPMT","name":"thiopurine S-methyltransferase"}],"object2s":[{"objCls":"Chemical","id":"PA448515","name":"azathioprine"}],"operator1":"and","operator2":"and","related":true,"terms":[{"id":769229935,"resource":"Phenotype Categories","term":"toxicity","termId":"secondaryCat:769229935"}]},{"id":1184519002,"history":[],"literature":[{"id":6690400,"resourceId":"21270794","title":"Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.","sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/21270794","type":"article"}],"object1s":[{"objCls":"Gene","id":"PA356","symbol":"TPMT","name":"thiopurine S-methyltransferase"}],"object2s":[{"objCls":"Chemical","id":"PA450379","name":"mercaptopurine"}],"operator1":"and","operator2":"and","related":true,"terms":[{"id":769229935,"resource":"Phenotype Categories","term":"toxicity","termId":"secondaryCat:769229935"}]},{"id":1184519003,"history":[],"literature":[{"id":6690400,"resourceId":"21270794","title":"Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.","sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/21270794","type":"article"}],"object1s":[{"objCls":"Gene","id":"PA356","symbol":"TPMT","name":"thiopurine S-methyltransferase"}],"object2s":[{"objCls":"Chemical","id":"PA451663","name":"thioguanine"}],"operator1":"and","operator2":"and","related":true,"terms":[{"id":769229935,"resource":"Phenotype Categories","term":"toxicity","termId":"secondaryCat:769229935"}]}]}